High-dose etoposide with granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem/progenitor cells in patients with hematologic malignancies.
- Author:
Hua LU
1
;
Jian-Yong LI
;
Zheng GE
;
Peng LIU
;
Yu-Jie WU
;
Han-Xin WU
;
Xiao-Yan ZHANG
;
Si-Xuan QIAN
;
Ming HONG
;
Run ZHANG
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Agents, Phytogenic;
administration & dosage;
Etoposide;
administration & dosage;
Female;
Granulocyte Colony-Stimulating Factor;
administration & dosage;
Hematologic Neoplasms;
blood;
therapy;
Hematopoietic Stem Cell Mobilization;
methods;
Humans;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
methods;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2006;14(2):397-399
- CountryChina
- Language:Chinese
-
Abstract:
To explore the efficacy and safety of high-dose of etoposide with granulocyte colony-stimulating factor (G-CSF) for mobilization of peripheral blood stem cells, 10 patients with hematologic malignancies including 6 patients with multiple myeloma and 4 with non Hodgkin' s lymphoma received an etoposide dose of 1.6 g/m2. The total dose of undiluted etoposide was given on day 1 as a continuous intravenous infusion via a central vein for 10 hours. G-CSF 5 microg/kg was used on day 3 and given daily subcutaneously until leukopheresis was completed. The results showed that leukopheresis was started at days 11 (range 9-13 days) following etoposide therapy, the mean number of CD34+ cells collected in all 10 patients was 9.4 x 10(6)/kg (range 4.2 - 17.3 x 10(6)/kg), by an average of 2.6 leukophereses (range 1-4) times. Mobilization procedure that produced yields of greater than 4.0 x 10(6)/kg were achieved in every patient. Toxicity showed oropharyngeal mucositis, faucitis and urethritis respectively in 3 patients. It is concluded that high-dose etoposide with G-CSF is an effective and safe mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with hematologic malignancies.
